Bain Capital Life Sciences Investors, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 12, 2024), Bain Capital Life Sciences Investors, LLC reported 24 stock positions worth $910.0 million. Its top holding was Nuvalent Class A (NUVL) at 22.5% of the portfolio, followed by Newamsterdam Pharma (NAMS, 22.1%) and Disc Medicine (IRON, 8.9%). Compared with Q1 2024, it opened 1 new position, sold out of 2, added to 6 and reduced 4. The biggest buy was Disc Medicine (IRON, shares +36%) and the biggest sale an exit from Madrigal Pharmaceuticals (MDGL).
- Most Recent 13F
- Q2 2026
- Location
- Boston, MA
- CIK
- 0001703031
- Portfolio Value
- $910.0M (Q2 2024)
- SEC Filing
- 0000950123-24-007830 ↗ filed Aug 12, 2024
Holdings Value
Holdings 24 stocks · $910.0M
| NUVL Nuvalent Inc. Class A | 22.49% | 2,697,267 | $204.6M | No change |
| NAMS Newamsterdam Pharma Co. NV | 22.11% | 10,473,913 | $201.2M | No change |
| IRON Disc Medicine Inc. | 8.89% | 1,795,735 | $80.9M | Add +36.3% |
| DNTH Dianthus Therapeutics Inc. | 8.57% | 3,013,423 | $78.0M | Add +0.7% |
| PHVS Pharvaris NV | 6.82% | 3,303,381 | $62.1M | No change |
| SVRA Savara Inc. | 6.45% | 14,565,457 | $58.7M | No change |
| ANNX Annexon Inc. | 4.55% | 8,449,208 | $41.4M | Reduce -2.9% |
| KYTX Kyverna Therapeutics Inc. | 2.78% | 3,368,370 | $25.3M | Add +6.5% |
| TNGX Tango Therapeutics Inc. | 2.73% | 2,892,663 | $24.8M | No change |
| SLDB Solid Biosciences Inc. | 2.51% | 4,034,582 | $22.9M | No change |
| MERSANA THERAPEUTICS INC | 1.91% | 8,663,673 | $17.4M | No change |
| SYRS Syros Pharmaceuticals Inc. | 1.56% | 2,749,808 | $14.2M | No change |
| IPSC Century Therapeutics Inc. | 1.52% | 5,410,361 | $13.8M | New |
| CABA Cabaletta Bio Inc. | 1.36% | 1,649,964 | $12.3M | Add +2.0% |
| XFOR X4 Pharmaceuticals Inc. | 1.08% | 16,915,784 | $9.8M | No change |
| ARQT Arcutis Biotherapeutics Inc. | 1.05% | 1,030,703 | $9.6M | Reduce -48.8% |
| AVIR Atea Pharmaceuticals Inc. | 0.90% | 2,485,638 | $8.2M | No change |
| RPID Rapid Micro Biosystems Inc. Class A | 0.61% | 8,434,560 | $5.6M | No change |
| CCCC C4 Therapeutics Inc. | 0.56% | 1,111,910 | $5.1M | Reduce -2.6% |
| NAUT Nautilus Biotechnology Inc. | 0.51% | 2,000,000 | $4.7M | No change |
| XLO Xilio Therapeutics Inc. | 0.39% | 3,785,450 | $3.6M | Add +34.9% |
| MRNS Marinus Pharmaceuticals Inc. | 0.29% | 2,267,680 | $2.7M | Add +62.8% |
| IVVD Invivyd Inc. | 0.22% | 1,799,595 | $2.0M | No change |
| ACRS Aclaris Therapeutics Inc. | 0.12% | 1,000,000 | $1.1M | Reduce -66.7% |
Other holdings (1): bonds, preferreds, convertibles and warrants · $872K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 100,000 | $872K | No change |
Total filed on the 13F, all lines: $910.8M.
Portfolio Sells Q1 2024 → Q2 2024
| MDGL Madrigal Pharmaceuticals Inc. | Sold out | 0.00% | −4.23 |
| NRIX Nurix Therapeutics Inc. | Sold out | 0.00% | −1.34 |
| ARQT Arcutis Biotherapeutics Inc. | Reduce -48.8% | 1.05% | −0.55 |
| ANNX Annexon Inc. | Reduce -2.9% | 4.55% | −0.47 |
| CCCC C4 Therapeutics Inc. | Reduce -2.6% | 0.56% | −0.19 |
| ACRS Aclaris Therapeutics Inc. | Reduce -66.7% | 0.12% | −0.18 |
Portfolio Buys Q1 2024 → Q2 2024
| IRON Disc Medicine Inc. | Add +36.3% | 8.89% | +2.30 |
| IPSC Century Therapeutics Inc. | New | 1.52% | +1.52 |
| DNTH Dianthus Therapeutics Inc. | Add +0.7% | 8.57% | +1.35 |
| XLO Xilio Therapeutics Inc. | Add +34.9% | 0.39% | +0.15 |
| MRNS Marinus Pharmaceuticals Inc. | Add +62.8% | 0.29% | −0.72 |
| CABA Cabaletta Bio Inc. | Add +2.0% | 1.36% | −0.86 |
| KYTX Kyverna Therapeutics Inc. | Add +6.5% | 2.78% | −3.55 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 20 | $1.7B | KLRA, HTFL, NAMS, SVRA, ALKS |
| Q1 2026 | 19 | $1.1B | HTFL, NAMS, OLMA, SVRA, PHVS |
| Q4 2025 | 18 | $1.3B | HTFL, NAMS, OLMA, SVRA, PHVS |
| Q3 2025 | 20 | $1.5B | HTFL, NAMS, CDTX, PHVS, OLMA |
| Q2 2025 | 22 | $798.5M | NAMS, CDTX, NUVL, PHVS, DNTH |
| Q1 2025 | 23 | $675.0M | NAMS, NUVL, PHVS, IRON, DNTH |
| Q4 2024 | 25 | $848.7M | NAMS, NUVL, PHVS, IRON, DNTH |
| Q3 2024 | 23 | $960.5M | NUVL, NAMS, IRON, DNTH, SVRA |
| Q2 2024 | 24 | $910.0M | NUVL, NAMS, IRON, DNTH, PHVS |
| Q1 2024 | 25 | $1.2B | NAMS, NUVL, DNTH, IRON, KYTX |